Chicago—Long-term hormone therapy can do more harm than good in men with low prostate-specific antigen (PSA) levels after surgery for recurrent prostate cancer, according to a secondary analysis of data from the NRG Oncology/RTOG 9601 clinical trial presented at the 2019 annual meeting of the American Society for Radiation Oncology.
Initial primary findings of the trial reported in 2017 indicated that adding two years of antiandrogen therapy to postsurgical radiation treatment for men with